```html

Ewing’s Angiitis (Primary Central Nervous System Vasculitis)

Overview

Ewing’s angiitis, more formally called **primary central nervous system (CNS) vasculitis**, is a rare inflammatory disease that targets the blood vessels of the brain and spinal cord without systemic involvement. The inflammation narrows or blocks small‑ and medium‑sized arteries, leading to reduced blood flow, ischemia, and sometimes hemorrhage.

Although the eponym “Ewing’s angiitis” is infrequently used in contemporary literature, it remains a useful historical term for the classic presentation of primary CNS vasculitis (PCNSV) first described by Dr. James Ewing in 1925.

• Typical age of onset: 30‑50 years, but cases range from childhood to late adulthood.
• Gender: Slight male predominance (≈ 55 % male).
• Prevalence: Estimated 2.4–3.0 cases per 1 million people per year in the United States (CDC, 2022). Because symptoms mimic other neurologic disorders, true prevalence may be under‑reported.

Symptoms

Symptoms reflect the territory of the affected vessels and can evolve over days to weeks. Early recognition is key because the disorder can progress rapidly.

Common neurological manifestations

• Headache: Persistent, often “pressure‑like,” may worsen with activity.
• Focal weakness: Weakness in one arm, leg, or the face (hemiparesis).
• Sensory deficits: Numbness, tingling, or loss of proprioception.
• Speech problems: Dysarthria or expressive aphasia when language centers are involved.
• Visual disturbances: Blurred vision, double vision, or visual field cuts.
• Seizures: Focal or generalized; seen in 30‑40 % of patients.
• Cognitive changes: Memory loss, confusion, or personality shifts.
• Ataxia: Unsteady gait or coordination problems.
• Vertigo/Dizziness: May mimic inner‑ear disorders.

Less common but notable symptoms

• Acute onset of stroke‑like deficits (e.g., sudden hemiplegia).
• Brain stem signs – dysphagia, hoarseness, or impaired eye movements.
• Psychiatric symptoms – depression, anxiety, or psychosis.
• Fever or constitutional “flu‑like” symptoms (present in ~10 % of cases).

Causes and Risk Factors

The exact trigger for primary CNS vasculitis remains unknown, but research points to an interplay of immune dysregulation, genetic susceptibility, and possibly infectious mimics.

Proposed mechanisms

• Autoimmune response: Aberrant T‑cell activation leads to cytokine release (IL‑6, TNF‑α) that damages endothelial cells.
• Molecular mimicry: Prior viral or bacterial infections (e.g., varicella‑zoster, hepatitis B) may prime the immune system.
• Genetic predisposition: HLA‑DRB1*04 and certain single‑nucleotide polymorphisms have been associated with higher risk (JAMA Neurol, 2021).

Risk factors

• Age 30‑50 (peak incidence).
• Male sex (modest increase).
• History of autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis).
• Recent viral infection or vaccination (temporal association, not causation).
• Familial clustering of vasculitic disorders (rare).

Diagnosis

Diagnosing primary CNS vasculitis is challenging because there is no single definitive test. Clinicians rely on a combination of clinical suspicion, imaging, laboratory studies, and—when safe—histopathology.

Step‑by‑step diagnostic pathway

1. Clinical assessment: Detailed neurologic exam and history to exclude more common causes (stroke, infection, tumors).
2. Laboratory screen: CBC, ESR, CRP, ANA, ANCA, complement levels, infectious serologies (HSV, VZV, HIV, hepatitis). Typically, inflammatory markers are modestly elevated; auto‑antibodies are usually negative in isolated PCNSV.
3. MRI of brain and spine (with and without contrast): The gold‑standard imaging tool.
   • Findings: Multifocal T2/FLAIR hyperintensities, leptomeningeal enhancement, infarcts in multiple vascular territories, and sometimes microhemorrhages on susceptibility‑weighted imaging.
4. Magnetic resonance angiography (MRA) / CT angiography (CTA): Detects vessel narrowing, “beading,” or irregularities in medium‑sized arteries.
5. Cerebrospinal fluid (CSF) analysis:
   • Typical results: Mild lymphocytic pleocytosis (≤ 30 cells/µL), elevated protein, normal glucose.
   • Helps rule out infection or leptomeningeal carcinomatosis.
6. Brain or meningeal biopsy (definitive): Reserved for atypical or refractory cases because of procedural risk.
   • Histology shows transmural inflammation, fibrinoid necrosis, and sometimes granulomatous changes.

Current diagnostic criteria (Calabrese & Mallek, 1988; revised 2019) require:

• Neurologic deficit unexplained by other disease.
• Imaging or histologic evidence of CNS vasculitis.
• Absence of systemic vasculitis or other identifiable cause.

Treatment Options

Prompt immunosuppression improves outcomes and reduces the risk of permanent neurologic deficit. Treatment is individualized based on severity, age, and comorbidities.

1. Induction therapy (rapid disease control)

• Corticosteroids: Intravenous methylprednisolone 1 g daily for 3–5 days, followed by oral prednisone 1 mg/kg/day, then taper over 6–12 months.
• Adjunct immunosuppressants:
  • Cyclophosphamide (IV 0.75 g/m² monthly × 6 months) – preferred for severe or life‑threatening disease.
  • Rituximab (375 mg/m² weekly × 4) – alternative for cyclophosphamide‑intolerant patients.

2. Maintenance therapy (prevent relapse)

• Mycophenolate mofetil 1–2 g/day or Azathioprine 2–2.5 mg/kg/day for 12–24 months.
• Low‑dose prednisone (≤ 10 mg/day) may be continued during the first year.

3. Targeted biologic agents (reserved for refractory disease)

• Tocilizumab (IL‑6 receptor blocker) – emerging data show remission in 60‑70 % of refractory PCNSV cases (Neurology, 2022).
• Infliximab or Adalimumab** – TNF‑α inhibitors used when vasculitis is associated with underlying autoimmune disease.

4. Supportive and procedural measures

• Antiplatelet therapy: Low‑dose aspirin (81 mg) is often added after acute ischemic events.
• Seizure control: Levetiracetam or another appropriate anticonvulsant.
• Physical & occupational therapy: To regain motor function and promote neuroplasticity.
• Vaccinations: Influenza, pneumococcal, and COVID‑19 vaccines before initiating long‑term immunosuppression.

5. Lifestyle modifications

• Quit smoking – reduces vascular inflammation.
• Adopt a Mediterranean‑style diet rich in omega‑3 fatty acids.
• Maintain blood pressure < 130/80 mmHg and optimal cholesterol.
• Regular low‑impact exercise (e.g., walking, swimming) as tolerated.

Living with Ewing’s Angiitis (Primary CNS Vasculitis)

While the disease can be intimidating, many patients achieve remission and lead productive lives. Below are practical tips to manage day‑to‑day challenges.

Medication management

• Use a weekly pill organizer; set phone alarms for dosing times.
• Keep a log of side effects (e.g., mood changes, hair loss, infections) and discuss them with your neurologist.
• Regular bloodwork (CBC, CMP, liver enzymes) every 4–6 weeks during induction, then every 3 months.

Monitoring neurologic status

• Perform a brief “brain check” each morning: note any new weakness, numbness, speech difficulty, or visual changes.
• Maintain a symptom diary to share with your care team.

Physical health

• Consult a physical therapist early to design a safe exercise plan.
• Stay hydrated and eat balanced meals; corticosteroids can raise blood sugar.
• Screen for osteoporosis (DEXA scan) if on high‑dose steroids > 3 months.

Emotional & social wellbeing

• Consider counseling or support groups—national vasculitis foundations host virtual meetings.
• Inform close friends and coworkers about your condition and emergency plan.
• Plan for “good days” and allow rest on “bad days” without guilt.

Follow‑up schedule

• Neurology: every 1–3 months during treatment, then bi‑annually in remission.
• Rheumatology (if co‑managed) or immunology for immunosuppressive therapy monitoring.
• MRI with contrast at 3 months, 6 months, and yearly thereafter, or sooner if symptoms worsen.

Prevention

Because primary CNS vasculitis is not fully understood, primary prevention is limited. However, general vascular health measures can lower the overall inflammatory burden.

• Control hypertension, diabetes, and hyperlipidemia.
• Avoid tobacco and excessive alcohol.
• Promptly treat infections; discuss prophylactic antivirals if you are on potent immunosuppression.
• Vaccinate according to CDC guidelines before starting immunosuppressive drugs.

Complications

If left untreated or inadequately controlled, Ewing’s angiitis can lead to serious, sometimes irreversible outcomes.

• Stroke or recurrent infarcts – leading to permanent motor or cognitive deficits.
• Intracerebral hemorrhage – can be life‑threatening.
• Seizure disorder – may become refractory.
• Chronic neurocognitive impairment – memory, executive function, and mood disturbances.
• Side‑effects of therapy – opportunistic infections, steroid‑induced diabetes, osteoporosis, malignancy risk with long‑term cyclophosphamide.

When to Seek Emergency Care

Prompt medical attention can prevent permanent damage and improve the chances of full recovery.

---

Sources: Mayo Clinic, CDC, National Institutes of Health (NIH), World Health Organization (WHO), Cleveland Clinic, JAMA Neurology 2021, Neurology Journal 2022, Calabrese & Mallek diagnostic criteria (1988, revised 2019).

```